An engineered immunotherapy (NKTR-214) with altered selectivity toward the IL2 receptor: Efficacy and tolerability in a murine tumor model.
Deborah H. Charych
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Murali Addepalli
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Steve Lee
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Thomas Chang
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Xiaofeng Liu
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Rhoneil Pena
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Terry Sweeney
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Ute Hoch
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Stephen K. Doberstein
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
Seema S. Kantak
Employment or Leadership Position - Nektar
Stock Ownership - Nektar